He noted that globally, it is observed that the SARS-CoV-2 virus isn’t fatal in children.,wap sbobet88
10bet phone number,“Only a very mild infection is present. In a few children, it’s milder than the common cold. Currently, we don’t have any justification on whether Zydus Cadila, Bharat Biotech, Pfizer or Moderna...which is the mildest. These vaccines are reducing the severity of the infection but not the infection,” he said.
dafabet dafasports,The professor also claimed that latest trials have shown that safety and immunogenicity of India’s indigenous Covid-19 vaccine – Covaxin – are almost the same in children as adults above 18 years of age.
barcelona news,“Covaxin’s trial was done on three age groups. The first group examined was between 12 -18 years, the second group was between 6- 12 years and the third age group was between 2-6 years,” Rai said.
best online betting sites offers,Rai was India’s principal investigator of Covaxin trials on children.
“At first, we finished the examination of people aged between 12- 18 years and then subsequently other groups. Covaxin’s vaccine safety and immunogenicity are almost the same. However, the final results of these trials are awaited. We had already carried out trials on the adult population. For children, we are waiting for the results,” he said.,cricket tutors